Table 2.
Diagnostic tests and treatment | Control (n = 758)1 | Intervention (n = 642)1 | P-value |
---|---|---|---|
In-hospital tests and procedures | |||
ECG, No. (%) | 751 (99.1) | 641 (99.8) | 0.06 |
Cardioversion, No. (%) | 23 (3.0) | 14 (2.2) | 0.32 |
Stress testing, No. (%) | 1 (0.1) | 0 (0.0) | 0.36 |
Coronary angiography, No. (%) | 163 (21.5) | 133 (20.7) | 0.72 |
Percutaneous coronary intervention, No. (%) | 45 (5.9) | 44 (6.9) | 0.48 |
Coronary artery bypass graft, No. (%) | 6 (0.8) | 9 (1.4) | 0.27 |
Implantable cardioverter defibrillator, No. (%) | 4 (0.5) | 3 (0.5) | 0.87 |
Cardiac resynchronization therapy, No. (%) | 1 (0.1) | 3 (0.5) | 0.24 |
Intra-aortic balloon pump, No. (%) | 0 (0.0) | 1 (0.2) | 0.28 |
Dialysis or ultrafiltration, No. (%) | 8 (1.1) | 9 (1.4) | 0.56 |
Non-invasive positive pressure ventilation, No. (%) | 218 (28.8) | 173 (26.9) | 0.45 |
Mechanical ventilation, No. (%) | 68 (9.0) | 57 (8.9) | 0.95 |
In-hospital treatment | |||
Loop diuretic, No. (%) | 713 (94.1) | 631 (98.3) | <0.001 |
Thiazide diuretic, No. (%) | 16 (2.1) | 16 (2.5) | 0.63 |
ACE-I or ARB, No. (%) | 310 (40.9) | 283 (44.1) | 0.23 |
Beta-blocker, No. (%) | 542 (71.5) | 478 (74.5) | 0.22 |
Aldosterone antagonist, No. (%) | 436 (57.5) | 431 (67.1) | <0.001 |
ARNi, No. (%) | 17 (2.2) | 8 (1.2) | 0.16 |
Digoxin No. (%) | 153 (20.2) | 107 (16.7) | 0.09 |
Ivabradine, No. (%) | 78 (10.3) | 70 (10.9) | 0.71 |
Aspirin, No. (%) | 632 (83.4) | 556 (86.6) | 0.09 |
Statin, No. (%) | 638 (84.2) | 559 (87.1) | 0.12 |
Hydralazine-nitrate, No. (%) | 45 (5.9) | 23 (3.6) | 0.04 |
Nitroglycerin, No. (%) | 219 (28.9) | 204 (31.8) | 0.24 |
Inotrope, No. (%) | 129 (17.0) | 126 (19.6) | 0.21 |
ECG: electrocardiogram, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, ARNi: angiotensin receptor neprilysin inhibitor
Data were completely reported for all variables in Table 2.